Leyden Labs Raises €40 Million in Latest Funding Round
Leyden Labs, a biotech company focused on developing products to protect people from known and new respiratory viruses, has successfully raised €40 million in its latest funding round. The round was led by the European Innovation Council (EIC) Fund, with participation from Invest-NL, the Gates Foundation Strategic Investment Fund, and ClavystBio.
Strategic Investment to Combat Respiratory Viruses
The funding, announced on June 25, 2026, will be pivotal in advancing Leyden Labs' nasal spray platform, which is designed to help protect against influenza and other respiratory viruses. This investment arrives following Leyden Labs' selection for the EIC STEP Scale Up programme, highlighting the company's growing recognition and support within the biotech industry.
Koenraad Wiedhaup, CEO and co-founder of Leyden Labs, expressed the significance of the funding, stating: "This financing represents much more than capital. It signals confidence in our scientific approach, our team, and our mission to fundamentally improve how the world protects itself against respiratory viruses."
Investor Contributions
Invest-NL played a notable role in the funding round, contributing €10 million. The involvement of these strategic investors underscores the potential impact of Leyden Labs' innovative approach to respiratory virus protection.
Company Leadership
Leyden Labs was co-founded by Dinko Valerio, who serves as the Executive Chairman, alongside Koenraad Wiedhaup. Their leadership and vision have been instrumental in guiding the company towards developing groundbreaking solutions in the field of respiratory health.
Utilization of Funds
The newly acquired funds will be directed towards further development and clinical advancement of Leyden Labs' nasal spray platform. This will include scaling up production capabilities and accelerating the path to global accessibility of their products.
Conclusion
The €40 million funding round marks a significant milestone for Leyden Labs as it continues to innovate in the field of biotechnology. With strong backing from prominent investors, the company is well-positioned to make strides in protecting global health against respiratory viruses.